Adrenocortical carcinoma risk factors: Difference between revisions
No edit summary |
No edit summary |
||
Line 5: | Line 5: | ||
The most potent risk factors in the development of adrenocortical cancer are [[Lynch syndrome]][[Beckwith-Wiedemann syndrome|, Beckwith-Wiedemann syndrome,]] [[Carney complex|Carney complex,]] [[Neurofibromatosis type I|Neurofibromatosis type 1,]] [[Multiple endocrine neoplasia type 1]] ([[MEN1]]), and [[Carney complex]]. | The most potent risk factors in the development of adrenocortical cancer are [[Lynch syndrome]][[Beckwith-Wiedemann syndrome|, Beckwith-Wiedemann syndrome,]] [[Carney complex|Carney complex,]] [[Neurofibromatosis type I|Neurofibromatosis type 1,]] [[Multiple endocrine neoplasia type 1]] ([[MEN1]]), and [[Carney complex]]. | ||
==Risk Factors== | ==Risk Factors== | ||
Risk | Risk factors associated with adrenocortical carcinoma are: | ||
* [[Lynch syndrome]] | * [[Lynch syndrome]]<ref name="pmid26309352">{{cite journal| author=Carethers JM, Stoffel EM| title=Lynch syndrome and Lynch syndrome mimics: The growing complex landscape of hereditary colon cancer. | journal=World J Gastroenterol | year= 2015 | volume= 21 | issue= 31 | pages= 9253-61 | pmid=26309352 | doi=10.3748/wjg.v21.i31.9253 | pmc=4541378 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26309352 }}</ref> | ||
*[[Beckwith-Wiedemann syndrome]] ([[Beckwith-Wiedemann syndrome|BWS]]) | *[[Beckwith-Wiedemann syndrome]] ([[Beckwith-Wiedemann syndrome|BWS]])<ref name=":0" /> | ||
*[[Carney complex]] | *[[Carney complex]]<ref name="pmid26130139">{{cite journal| author=Correa R, Salpea P, Stratakis CA| title=Carney complex: an update. | journal=Eur J Endocrinol | year= 2015 | volume= 173 | issue= 4 | pages= M85-97 | pmid=26130139 | doi=10.1530/EJE-15-0209 | pmc=4553126 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26130139 }}</ref> | ||
*[[Neurofibromatosis type I|Neurofibromatosis type 1]] | *[[Neurofibromatosis type I|Neurofibromatosis type 1]] <ref name="pmid250305152" /> | ||
*[[Multiple endocrine neoplasia type 1]] ([[MEN1]]) | *[[Multiple endocrine neoplasia type 1]]([[MEN1]])<ref name=":1" /> | ||
{| style="border: 0px; font-size: 90%; margin: 3px; width: 1000px" align="center" | {| style="border: 0px; font-size: 90%; margin: 3px; width: 1000px" align="center" | ||
Line 18: | Line 18: | ||
! style="background: #4479BA; width: 300px;" | {{fontcolor|#FFF|Clinical picture}} | ! style="background: #4479BA; width: 300px;" | {{fontcolor|#FFF|Clinical picture}} | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |[[Lynch syndrome]] | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |[[Lynch syndrome]]<ref name="pmid26309352" /> | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* [[MSH2]], [[MSH6]], [[MLH1]], [[PMS2]] | * [[MSH2]], [[MSH6]], [[MLH1]], [[PMS2]] | ||
Line 29: | Line 29: | ||
* [[Brain cancer]] | * [[Brain cancer]] | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |[[Neurofibromatosis type I|Neurofibromatosis type 1]] | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |[[Neurofibromatosis type I|Neurofibromatosis type 1]] <ref name="pmid250305152">{{cite journal| author=Hirbe AC, Gutmann DH| title=Neurofibromatosis type 1: a multidisciplinary approach to care. | journal=Lancet Neurol | year= 2014 | volume= 13 | issue= 8 | pages= 834-43 | pmid=25030515 | doi=10.1016/S1474-4422(14)70063-8 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25030515 }}</ref> | ||
| | | | ||
* [[NF1]] | * [[NF1]] | ||
Line 41: | Line 41: | ||
* Skeletal abnormalities | * Skeletal abnormalities | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |[[Multiple endocrine neoplasia type 1|MEN1]]<ref>{{Cite journal | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |[[Multiple endocrine neoplasia type 1|MEN1]]<ref name=":1">{{Cite journal | ||
| author = [[B. Gatta-Cherifi]], [[O. Chabre]], [[A. Murat]], [[P. Niccoli]], [[C. Cardot-Bauters]], [[V. Rohmer]], [[J. Young]], [[B. Delemer]], [[H. Du Boullay]], [[M. F. Verger]], [[J. M. Kuhn]], [[J. L. Sadoul]], [[Ph Ruszniewski]], [[A. Beckers]], [[M. Monsaingeon]], [[E. Baudin]], [[P. Goudet]] & [[A. Tabarin]] | | author = [[B. Gatta-Cherifi]], [[O. Chabre]], [[A. Murat]], [[P. Niccoli]], [[C. Cardot-Bauters]], [[V. Rohmer]], [[J. Young]], [[B. Delemer]], [[H. Du Boullay]], [[M. F. Verger]], [[J. M. Kuhn]], [[J. L. Sadoul]], [[Ph Ruszniewski]], [[A. Beckers]], [[M. Monsaingeon]], [[E. Baudin]], [[P. Goudet]] & [[A. Tabarin]] | ||
Line 64: | Line 64: | ||
* [[Adrenal adenoma]]/[[hyperplasia]] | * [[Adrenal adenoma]]/[[hyperplasia]] | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |[[Carney complex]] | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |[[Carney complex]]<ref name="pmid26130139" /> | ||
| | | | ||
* [[PRKAR1A]] | * [[PRKAR1A]] | ||
Line 74: | Line 74: | ||
* [[Somatotrope|Somatotroph]] [[pituitary adenoma]] | * [[Somatotrope|Somatotroph]] [[pituitary adenoma]] | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |[[BWS]]<ref>{{Cite journal | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |[[BWS]]<ref name=":0">{{Cite journal | ||
| author = [[H. Segers]], [[R. Kersseboom]], [[M. Alders]], [[R. Pieters]], [[A. Wagner]] & [[M. M. van den Heuvel-Eibrink]] | | author = [[H. Segers]], [[R. Kersseboom]], [[M. Alders]], [[R. Pieters]], [[A. Wagner]] & [[M. M. van den Heuvel-Eibrink]] |
Revision as of 15:06, 26 September 2017
Adrenocortical carcinoma Microchapters |
Differentiating Adrenocortical carcinoma from other Diseases |
---|
Diagnosis |
Treatment |
Case Study |
Adrenocortical carcinoma risk factors On the Web |
American Roentgen Ray Society Images of Adrenocortical carcinoma risk factors |
Risk calculators and risk factors for Adrenocortical carcinoma risk factors |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmad Al Maradni, M.D. [2] Mohammed Abdelwahed M.D[3]
Overview
The most potent risk factors in the development of adrenocortical cancer are Lynch syndrome, Beckwith-Wiedemann syndrome, Carney complex, Neurofibromatosis type 1, Multiple endocrine neoplasia type 1 (MEN1), and Carney complex.
Risk Factors
Risk factors associated with adrenocortical carcinoma are:
- Lynch syndrome[1]
- Beckwith-Wiedemann syndrome (BWS)[2]
- Carney complex[3]
- Neurofibromatosis type 1 [4]
- Multiple endocrine neoplasia type 1(MEN1)[5]
Differential Diagnosis | Gene mutations | Clinical picture |
---|---|---|
Lynch syndrome[1] | ||
Neurofibromatosis type 1 [4] |
| |
MEN1[5] |
|
|
Carney complex[3] | ||
BWS[2] |
References
- ↑ 1.0 1.1 Carethers JM, Stoffel EM (2015). "Lynch syndrome and Lynch syndrome mimics: The growing complex landscape of hereditary colon cancer". World J Gastroenterol. 21 (31): 9253–61. doi:10.3748/wjg.v21.i31.9253. PMC 4541378. PMID 26309352.
- ↑ 2.0 2.1 H. Segers, R. Kersseboom, M. Alders, R. Pieters, A. Wagner & M. M. van den Heuvel-Eibrink (2012). "Frequency of WT1 and 11p15 constitutional aberrations and phenotypic correlation in childhood Wilms tumour patients". European journal of cancer (Oxford, England : 1990). 48 (17): 3249–3256. doi:10.1016/j.ejca.2012.06.008. PMID 22796116. Unknown parameter
|month=
ignored (help) - ↑ 3.0 3.1 Correa R, Salpea P, Stratakis CA (2015). "Carney complex: an update". Eur J Endocrinol. 173 (4): M85–97. doi:10.1530/EJE-15-0209. PMC 4553126. PMID 26130139.
- ↑ 4.0 4.1 Hirbe AC, Gutmann DH (2014). "Neurofibromatosis type 1: a multidisciplinary approach to care". Lancet Neurol. 13 (8): 834–43. doi:10.1016/S1474-4422(14)70063-8. PMID 25030515.
- ↑ 5.0 5.1 B. Gatta-Cherifi, O. Chabre, A. Murat, P. Niccoli, C. Cardot-Bauters, V. Rohmer, J. Young, B. Delemer, H. Du Boullay, M. F. Verger, J. M. Kuhn, J. L. Sadoul, Ph Ruszniewski, A. Beckers, M. Monsaingeon, E. Baudin, P. Goudet & A. Tabarin (2012). "Adrenal involvement in MEN1. Analysis of 715 cases from the Groupe d'etude des Tumeurs Endocrines database". European journal of endocrinology. 166 (2): 269–279. doi:10.1530/EJE-11-0679. PMID 22084155. Unknown parameter
|month=
ignored (help)